Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Study Phase
Phase 3
Study Completion Date
September 2006
NCT00081796Uploaded 04-29-2015
Available for Download
PDS UID: Breast_SanofiU_2004_135
A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy
PDS UID: Breast_Multipl_2004_414Go to Study
Enhancing the Analytic Capacity of Breast_SanofiU_2004_135 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey
DATA DICTIONARYsanofi_XRP9881_EFC6089_datasphere_data_definition.xls
DATA SUMMARYProc Contents Data Dictionary PDS135.pdf
DATA (COMPARATOR ARM)sanofi_xrp9881_efc6089_datasets_and